CureVac Publishes Results of CVnCoV in Interim P-l Study for COVID-19

 CureVac Publishes Results of CVnCoV in Interim P-l Study for COVID-19

CureVac Publishes Results of CVnCoV in Interim P-l Study for COVID-19

Shots:

  • The P-l study involves assessing CVnCoV in patients with COVID-19. The interim data showed that CVnCoV (2-12µg) was well tolerated and induced strong binding and neutralizing Ab responses to the first indication of T cell activation
  • The immune response was found to be comparable to recovered COVID-19 patients, closely mimicking the immune response after natural COVID-19 infection. The manuscript is available on medRxiv and will be submitted for publication in a peer-reviewed journal
  • The P-l clinical study began in June 2020 in Germany and Belgium in collaboration with the CEPI. CureVac plans to initiate a pivotal P-IIb/III clinical study by the end of 2020

Click here ­to­ read full press release/ article | Ref: CureVac | Image: CNN

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post